Relx’s (REL) “Buy” Rating Reaffirmed at Berenberg Bank

Relx (LON:REL)‘s stock had its “buy” rating reissued by research analysts at Berenberg Bank in a research note issued on Monday. They currently have a GBX 1,850 ($24.17) target price on the stock. Berenberg Bank’s price objective would suggest a potential upside of 12.46% from the stock’s previous close.

REL has been the subject of several other research reports. Societe Generale reiterated a “buy” rating and issued a GBX 1,840 ($24.04) price objective on shares of Relx in a research report on Friday, January 25th. Deutsche Bank lowered their target price on Relx from GBX 1,820 ($23.78) to GBX 1,785 ($23.32) and set a “buy” rating on the stock in a report on Tuesday, December 4th. Liberum Capital reissued a “buy” rating on shares of Relx in a report on Friday. Goldman Sachs Group upped their target price on Relx from GBX 2,006 ($26.21) to GBX 2,167 ($28.32) and gave the company a “buy” rating in a report on Monday, January 14th. Finally, HSBC raised Relx to a “buy” rating and upped their target price for the company from GBX 1,830 ($23.91) to GBX 1,870 ($24.43) in a report on Monday, January 7th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of GBX 1,788.08 ($23.36).

Get Relx alerts:

LON:REL traded up GBX 34.50 ($0.45) during trading hours on Monday, hitting GBX 1,645 ($21.49). The company’s stock had a trading volume of 3,818,366 shares, compared to its average volume of 4,990,000. Relx has a 52-week low of GBX 1,399 ($18.28) and a 52-week high of GBX 1,784 ($23.31).

In other Relx news, insider Erik Engstrom sold 36,334 shares of the company’s stock in a transaction on Friday, February 22nd. The stock was sold at an average price of GBX 1,770 ($23.13), for a total value of £643,111.80 ($840,339.47).

Relx Company Profile

RELX PLC provides information and analytics for professional and business customers in the United States and internationally. It operates through four segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment provides information and analytics to institutions and professionals.

Featured Article: Find a Trading Strategy That Works